Cell Biology and Toxicology

, Volume 25, Issue 3, pp 217–225

Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase

  • Alan R. Parrish
  • Gang Chen
  • Robert C. Burghardt
  • Takaho Watanabe
  • Christophe Morisseau
  • Bruce D. Hammock


Cisplatin is a highly effective chemotherapeutic agent against many tumors; however, it is also a potent nephrotoxicant. Given that there have been no significant advances in our ability to clinically manage acute renal failure since the advent of dialysis, the development of novel strategies to ablate nephrotoxicity would represent a significant development. In this study, we investigated the ability of an inhibitor of soluble epoxide hydrolase (sEH), n-butyl ester of 12-(3-adamantan-1-yl-ureiido)-dodecanoic acid (nbAUDA), to attenuate cisplatin-induced nephrotoxicity. nbAUDA is quickly converted to AUDA and results in maintenance of high AUDA levels in vivo. Subcutaneous administration of 40 mg/kg of nbAUDA to C3H mice every 24 h resulted in elevated blood levels of AUDA; this protocol was also associated with attenuation of nephrotoxicity induced by cisplatin (intraperitoneal injection) as assessed by BUN levels and histological evaluation of kidneys. This is the first report of the use of sEH inhibitors to protect against acute nephrotoxicity and suggests a therapeutic potential of these compounds.


Cisplatin Nephrotoxicity Soluble epoxide hydrolase 


  1. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23:460–4.PubMedCrossRefGoogle Scholar
  2. Arany I, Herbert J, Herbert Z, Safirstein RL. Restoration of CREB function ameliorates cisplatin nephrotoxicity in renal tubular cells. Am J Physiol Renal Physiol 2008;294:F577–F581.PubMedCrossRefGoogle Scholar
  3. Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev. 1999;31:971–97.PubMedCrossRefGoogle Scholar
  4. Bonventre JV. Pathophysiology of acute kidney injury: roles of potential inhibitors of inflammation. Contrib Nephrol. 2007;156:39–46.PubMedCrossRefGoogle Scholar
  5. Chirino YI, Sanchez-Gonzalez DJ, Martinez-Martinez CM, Cruz C, Pedraza-Chaverri J. Protective effects of apocynin against cisplatin-induced oxidative stress and nephrotoxicity. Toxicology 2008;245:18–23.PubMedCrossRefGoogle Scholar
  6. Chirino YI, Trujillo J, Sanchez-Gonzalez DJ, Martinez-Martinez CM, Cruz C, Bobadilla NA, et al. Selective iNOS inhibition reduces renal damage induced by cisplatin. Toxicol Lett. 2007;176:48–57.PubMedCrossRefGoogle Scholar
  7. Francescato HD, Costa RS, Junior FB, Coimbra TM. Effect of JNK inhibition on cisplatin-induced renal damage. Nephrol Dial Transplant. 2007;22:2138–48.PubMedCrossRefGoogle Scholar
  8. Genvresse I, Lange C, Schanz J, Schweigert M, Harder H, Possinger K, et al. Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. Anticancer Drugs. 2001;12:345–9.PubMedCrossRefGoogle Scholar
  9. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999;17:409–22.PubMedGoogle Scholar
  10. Hannigan MH, Devarajan P. Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther. 2003;1:47–61.Google Scholar
  11. Hartmann JT, Fels LM, Knop S, Stolt H, Kanz L, Bokemeyer C. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs. 2000;18:281–9.PubMedCrossRefGoogle Scholar
  12. Hennig B, Hammock BD, Slim R, Toborek M, Saraswathi V, Robertson LW. PCB-induced oxidative stress in endothelial cells: Modulation by nutrients. Int J Hyg Environ Health. 2002;205:95–102.PubMedCrossRefGoogle Scholar
  13. Huang Q, Dunn RT 2nd, Jayadev S, DiSorbo Q, Pack RD, Farr SB, Stoll RE, Blanchard KT. Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol Sci. 2001;63:196–207.PubMedCrossRefGoogle Scholar
  14. Hung YC, Huang GS, Lin LW, Hong MY, Se PS. Thea sinensis melanin prevents cisplatin-induced nephrotoxicity in mice. Food Chem Toxicol. 2007;45:1123–30.PubMedCrossRefGoogle Scholar
  15. Imig JD. Eicosanoids and renal damage in cardiometabolic syndrome. Expert Opin Drug Metab Toxicol. 2008;4:165–74.PubMedCrossRefGoogle Scholar
  16. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 2002;39:690–4.PubMedCrossRefGoogle Scholar
  17. Inceoglu B, Jinks SL, Schmelzer KR, Waite T, Kim IH, Hammock BD. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci. 2006;79:2311–9.PubMedCrossRefGoogle Scholar
  18. Jiang J, Dean D, Burghardt RC, Parrish AR. Disruption of cadherin/catenin expression, localization, and interactions during HgCl2-induced nephrotoxicity. Toxicol Sci. 2004;80:170–82.PubMedCrossRefGoogle Scholar
  19. Jo SK, Cho WY, Sung SA, Kim HK, Won NH. MEK inhibitor, UO126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int. 2005;67:458–66.PubMedCrossRefGoogle Scholar
  20. Kim I-H, Nishi K, Tsai H-J, Bradford T, Koda Y, Watanabe T, et al. Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido) dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase. Bioorg Med Chem. 2007;15:312–23.PubMedCrossRefGoogle Scholar
  21. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001;24:19–38.PubMedCrossRefGoogle Scholar
  22. Kuwana H, Terada Y, Kobayashi T, Okado T, Penninger JM, Irie-Sasaki J, et al. The phosphoinositide-3 kinase gamma-AKT pathway mediates renal tubular injury in cisplatin nephrotoxicity. Kidney Int. 2008;73:430–45.PubMedCrossRefGoogle Scholar
  23. Lee S, Kim W, Moon SO, Sung MJ, Kim DH, Kang KP, et al. Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant. 2006;21:2096–105.PubMedCrossRefGoogle Scholar
  24. Li S, Gokden N, Okusa MD, Bhatt R, Portilla D. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol. 2005;289:F469–80.PubMedCrossRefGoogle Scholar
  25. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, et al. The anti-inflammatory effect of laminar flow: the role of PPARg, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci USA. 2005;102:16747–52.PubMedCrossRefGoogle Scholar
  26. Lokich J. What is the “best” platinum: Cisplatin, carboplatin, or oxaliplatin? Cancer Invest. 2001;19:756–60.PubMedCrossRefGoogle Scholar
  27. Ludwig T, Oberleithner H. Platinum toxicity in cultured renal epithelia. Cell Physiol Biochem. 2004;14:431–40.PubMedCrossRefGoogle Scholar
  28. Morisseau C, Goodrow MH, Dowdy D, Zheng J, Greene JF, Sanborn JR, et al. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci USA. 1999;96:8849–54.PubMedCrossRefGoogle Scholar
  29. Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, Hammock BD. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol. 2002;63:1599–608.PubMedCrossRefGoogle Scholar
  30. Node K, Huo Y, Ruan Y, Yang B, Spiecker M, Ley K, et al. Antiinflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999;285:1276–9.PubMedCrossRefGoogle Scholar
  31. Peyrou M, Cribb AE. Effect of endoplasmic reticulum stress preconditioning on cytotoxicity of clinically relevant nephrotoxins in renal cell lines. Toxicol In Vitro. 2007;21:878–86.PubMedGoogle Scholar
  32. Peyrou M, Hanna PE, Cribb AE. Cisplatin, gentamicin, and p-aminophenol induce markers of endoplasmic reticulum stress in the rat kidneys. Toxicol Sci. 2007;99:346–53.PubMedCrossRefGoogle Scholar
  33. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002;110:835–42.PubMedGoogle Scholar
  34. Ramesh G, Zhang B, Uematsu S, Akira S, Reeves WB. Endotoxin and cisplatin synergistically induce renal dysfunction and cytokine production in mice. Am J Physiol Renal Physiol. 2007;293:F325–32.PubMedCrossRefGoogle Scholar
  35. Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis. 1986;8:368–79.PubMedGoogle Scholar
  36. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002;82:131–85.PubMedGoogle Scholar
  37. Schaeppi U, Heyman IA, Fleischman RW, Rosenkrantz H, Ilievski V, Phelan R, et al. cis-dichlorodiammineplatinum(II) (NSC-119 875): Preclinical toxicologic evaluation of intravenous injection in dogs, monkeys and mice. Toxicol Appl Pharmacol. 1973;25:230–41.PubMedCrossRefGoogle Scholar
  38. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA. 2005;102:9772–7.PubMedCrossRefGoogle Scholar
  39. Schmelzer KR, Inceoglu B, Kubala L, Kim IH, Jinks SL, Eiserich JP, et al. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA. 2006;103:13646–51.PubMedCrossRefGoogle Scholar
  40. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem. 2000;275:40504–10.PubMedCrossRefGoogle Scholar
  41. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock BD. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci USA. 2005;102:2186–91.PubMedCrossRefGoogle Scholar
  42. Thompson KL, Afshari CA, Amin RP, Bertram TA, Car B, Cunningham M, et al. Identification of platform-independent gene expression markers of cisplatin nephrotoxicity. Environ Health Perspect. 2004;112:488–94.PubMedGoogle Scholar
  43. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol. 2003;14:1–10.PubMedCrossRefGoogle Scholar
  44. Watanabe T, Schulz D, Morisseau C, Hammock BD. High-throughput pharmacokinetic method: Cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysis. Anal Chim Acta. 2006;559:37–44.PubMedCrossRefGoogle Scholar
  45. Winston JA, Safirstein R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol. 1985;249:F490–6.PubMedGoogle Scholar
  46. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA. 2006;103:18733–38.PubMedCrossRefGoogle Scholar
  47. Yang C, Kaushal V, Haun RS, Seth R, Shah SV, Kaushal GP. Transcriptional activation of caspase-6 and -7 genes by cisplatin-induced p53 and its functional significance in cisplatin nephrotoxicity. Cell Death Differ. 2008;15:530–44.PubMedCrossRefGoogle Scholar
  48. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res. 2000;87:992–8.PubMedGoogle Scholar
  49. Zager RA, Johnson AC, Lund S, Randolph-Habecker J. Toll-like receptor (TLR4) shedding and depletion: acute proximal tubular cell responses to hypoxic and toxic injury. Am J Physiol Renal Physiol. 2007;292:F304–12.PubMedCrossRefGoogle Scholar
  50. Zeldin DC, Kobayashi J, Falck JR, Winder BS, Hammock BD, Snapper JR, et al. Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J Biol Chem. 1993;268:6402–7.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Alan R. Parrish
    • 1
  • Gang Chen
    • 1
  • Robert C. Burghardt
    • 2
  • Takaho Watanabe
    • 3
    • 4
  • Christophe Morisseau
    • 4
  • Bruce D. Hammock
    • 4
  1. 1.Department of Systems Biology and Translational Medicine, College of MedicineTexas A&M Health Science CenterCollege StationUSA
  2. 2.Department of Veterinary Integrated Biosciences, College of Veterinary MedicineTexas A&M UniversityCollege StationUSA
  3. 3.Food and Drug Safety CenterHatano Research InstituteHadanoJapan
  4. 4.Department of Entomology and UCD Cancer CenterUniversity of California at DavisDavisUSA

Personalised recommendations